New Alzheimer's drugs have brought cautious optimism to families and clinicians searching for better Alzheimer's treatment, but they also raise questions about effectiveness, safety, and access. These dementia drugs promise to slow cognitive decline rather than simply ease symptoms, yet their real‑world impact is modest and limited to specific patients.
